Apellis Pharmaceuticals Inc (NASDAQ:APLS) has a beta value of 0.88 and has seen 2.72 million shares traded in the last trading session. The company, currently valued at $4.24B, closed the last trade at $30.77 per share which meant it gained $3.02 on the day or 10.88% during that session. The APLS stock price is -139.84% off its 52-week high price of $73.80 and 20.9% above the 52-week low of $24.34. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.28 million shares traded. The 3-month trading volume is 2.85 million shares.
The consensus among analysts is that Apellis Pharmaceuticals Inc (APLS) is Buy stock at the moment, with a recommendation rating of 1.65. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 2 out of 14 have rated it as a Hold, with 11 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.37.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Apellis Pharmaceuticals Inc (NASDAQ:APLS) trade information
Sporting 10.88% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the APLS stock price touched $30.77 or saw a rise of 0.71%. Year-to-date, Apellis Pharmaceuticals Inc shares have moved -48.60%, while the 5-day performance has seen it change 17.13%. Over the past 30 days, the shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS) have changed 11.57%. Short interest in the company has seen 20.79 million shares shorted with days to cover at 7.13.
Wall Street analysts have a consensus price target for the stock at $76, which means that the shares’ value could jump 59.51% from current levels. The projected low price target is $39.0 while the price target rests at a high of $113.0. In that case, then, we find that the current price level is -267.24% off the targeted high while a plunge would see the stock gain -26.75% from current levels.
Apellis Pharmaceuticals Inc (APLS) estimates and forecasts
Figures show that Apellis Pharmaceuticals Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -24.23% over the past 6 months, with this year growth rate of 61.57%, compared to 18.00% for the industry. Revenue growth from the last financial year stood is estimated to be 91.84%.
18 analysts offering their estimates for the company have set an average revenue estimate of 191.93M for the current quarter. 9 have an estimated revenue figure of 193.43M for the next ending quarter. Year-ago sales stood 146.38M and 172.32M respectively for this quarter and the next, and analysts expect sales will grow by 31.12% for the current quarter and 91.84% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -13.70% over the past 5 years. Earnings growth for 2024 is a modest 62.25% while over the next 5 years, the company’s earnings are expected to increase by 33.30%.
APLS Dividends
Apellis Pharmaceuticals Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Apellis Pharmaceuticals Inc (NASDAQ:APLS)’s Major holders
Insiders own 13.98% of the company shares, while shares held by institutions stand at 97.47% with a share float percentage of 113.30%. Investors are also buoyed by the number of investors in a company, with Apellis Pharmaceuticals Inc having a total of 379.0 institutions that hold shares in the company. The top two institutional holders are WELLINGTON MANAGEMENT GROUP LLP with over 16.39 million shares worth more than $628.67 million. As of 2024-06-30, WELLINGTON MANAGEMENT GROUP LLP held 13.2269% of shares outstanding.
The other major institutional holder is ECOR1 CAPITAL, LLC, with the holding of over 11.61 million shares as of 2024-06-30. The firm’s total holdings are worth over $445.26 million and represent 9.3681% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Specialized-Health Care Fund and Vanguard Total Stock Market Index Fund . As of Jul 31, 2024 , the former fund manager holds about 8.11% shares in the company for having 10.09 shares of worth $310.43 million while later fund manager owns 3.3 shares of worth $101.46 million as of Jun 30, 2024 , which makes it owner of about 2.65% of company’s outstanding stock.
